Amrutanjan Health Care Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹123Cr
- +5.1% YoY
- +11.8% QoQ
- Net profit
- ₹19Cr
- +11.8% YoY
- +58.3% QoQ
- Margin
- 19%
- +1 pp YoY
- +7 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr). Quarterly EBITDA/Operating Margin:.
From Amrutanjan Health Care Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr)
- Q3 FY25 Net Sales - OTC: Rs. 117.86 Cr, up 5.43% YoY (Q3 FY24: Rs. 111.79 Cr)
- Q3 FY25 Net Sales - Comfy: Rs. 29.93 Cr, up slightly from Rs. 29.36 Cr YoY
- Q3 FY25 Net Sales - Beverages: Rs. 4.42 Cr, down from Rs. 5.18 Cr YoY
- Q3 FY25 Net Sales - Electro Plus: Rs. 4.31 Cr, down from Rs. 4.62 Cr YoY
- YTD Dec’24 Net Sales: Rs. 316.40 Cr, up 7.56% YoY (YTD Dec’23: Rs. 294.17 Cr)
- YTD Dec’24 OTC Division Sales: Rs. 296.75 Cr, up 9.09% YoY (YTD Dec’23: Rs. 272.02 Cr)
- Pain balm consumption volume growth in Dec quarter: 9.1% (IQVIA), highest in 20 quarters (excluding COVID)
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 123 | 117 | +5.1% | 110 | +11.8% |
| Operating profit (EBITDA) | 23 | 22 | +4.5% | 14 | +64.3% |
| Operating margin | 19% | 18% | +1 pp | 12% | +7 pp |
| Profit before tax | 26 | 24 | +8.3% | 16 | +62.5% |
| Net profit (PAT) | 19 | 17 | +11.8% | 12 | +58.3% |
| EPS (₹) | 6.66 | 6.04 | +10.3% | 4.08 | +63.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q3 FY25 results?
Q3 FY25 Net Sales: Rs. 122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. 116.99 Cr). Quarterly EBITDA/Operating Margin:.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
